{"id":83806,"date":"2022-12-25T21:03:33","date_gmt":"2022-12-25T19:03:33","guid":{"rendered":"https:\/\/www.csregypt.com\/?p=83806"},"modified":"2022-12-25T21:03:33","modified_gmt":"2022-12-25T19:03:33","slug":"eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment","status":"publish","type":"post","link":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/","title":{"rendered":"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment"},"content":{"rendered":"<p dir=\"ltr\" style=\"text-align: left;\">The <a href=\"https:\/\/www.csregypt.com\/en\/eib-banque-misr-team-up-to-further-support-smes\/\">European Investment Bank (EIB)<\/a> has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases.<\/p>\n<p dir=\"ltr\" style=\"text-align: left;\">Affibody is a Swedish clinical stage biotech company. It specialises in the development of next-generation biopharmaceuticals based on a proprietary technology, targeting unmet medical needs in immunology and oncology.<\/p>\n<p dir=\"ltr\" style=\"text-align: left;\">The investment will support Affibody\u2019s research and development (R&amp;D) activities in Europe in next-generation biopharmaceuticals to treat inflammatory diseases and cancer. It is expected to create over 100 jobs in this sector, and to boost the competitiveness of the EU biotech sector.<\/p>\n<p dir=\"ltr\" style=\"text-align: left;\">Paolo Gentiloni, European Commissioner for Economy, said: \u201cFacilitating the development of innovative treatments to tackle cancer and other serious diseases is among the worthiest investments we can make. This agreement, supported by InvestEU, is a further step towards ensuring Europe remains at the cutting edge of medical research and development.\u201d<\/p>\n<p dir=\"ltr\" style=\"text-align: left;\">EIB Vice-President Thomas \u00d6stros,\u00a0responsible for Sweden, said:\u201cSupporting promising biotech companies in the clinical stage is crucial for furthering the competitiveness of Europe\u2019s health and life sciences sector. This project is well aligned with the EIB\u2019s investment strategy and our aim to support highly innovative biotech companies, developing breakthrough life sciences products that have the potential to transform and greatly improve people\u2019s lives. As such, we are pleased to support Affibody\u2019s cutting-edge research into therapeutic solutions for cancer and inflammatory diseases, helping the company develop next-generation biopharmaceuticals.\u201d<\/p>\n<p dir=\"ltr\" style=\"text-align: left;\">Chief Executive Officer of Affibody David Bejkersaid<strong>\u00a0<\/strong><em>\u201c<\/em>We are very pleased and grateful for the support of the EIB, which will help us move towards the first potential market approvals of a new class of biologicals that can improve and prolong the lives of a number of patient groups.\u201d<\/p>\n<p dir=\"ltr\" style=\"text-align: left;\">\n","protected":false},"excerpt":{"rendered":"<p>The European Investment Bank (EIB) has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases. Affibody is a Swedish clinical stage biotech company. It specialises in the development of next-generation biopharmaceuticals based on a proprietary technology, targeting unmet medical needs in immunology and [&hellip;]<\/p>\n","protected":false},"author":410,"featured_media":83807,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6031,984],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment - Csr Egypt<\/title>\n<meta name=\"description\" content=\"(EIB) has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment - Csr Egypt\" \/>\n<meta property=\"og:description\" content=\"(EIB) has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Csr Egypt\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/csregypt\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-25T19:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"362\" \/>\n\t<meta property=\"og:image:height\" content=\"463\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marwa Zein\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:site\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marwa Zein\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/\"},\"author\":{\"name\":\"Marwa Zein\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\"},\"headline\":\"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment\",\"datePublished\":\"2022-12-25T19:03:33+00:00\",\"dateModified\":\"2022-12-25T19:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg\",\"articleSection\":[\"health\",\"news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/\",\"url\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/\",\"name\":\"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment - Csr Egypt\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg\",\"datePublished\":\"2022-12-25T19:03:33+00:00\",\"dateModified\":\"2022-12-25T19:03:33+00:00\",\"description\":\"(EIB) has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases.\",\"breadcrumb\":{\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage\",\"url\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg\",\"contentUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg\",\"width\":362,\"height\":463,\"caption\":\"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/csregypt.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/csregypt.com\/#website\",\"url\":\"https:\/\/csregypt.com\/\",\"name\":\"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631\",\"description\":\"The first portal for CSR in Egypt and Middle East\",\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/csregypt.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/csregypt.com\/#organization\",\"name\":\"CSR\",\"url\":\"https:\/\/csregypt.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"contentUrl\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"width\":1080,\"height\":1080,\"caption\":\"CSR\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/csregypt\/\",\"https:\/\/x.com\/egyptcsrforum\",\"https:\/\/www.instagram.com\/csr.egypt\/\",\"https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/\",\"https:\/\/www.pinterest.com.au\/csregypt\/\",\"https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\",\"name\":\"Marwa Zein\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"caption\":\"Marwa Zein\"},\"sameAs\":[\"http:\/\/marwazein1982@gmail.com\"],\"url\":\"https:\/\/csregypt.com\/en\/author\/marwa-zein\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment - Csr Egypt","description":"(EIB) has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment - Csr Egypt","og_description":"(EIB) has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases.","og_url":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/","og_site_name":"Csr Egypt","article_publisher":"https:\/\/www.facebook.com\/csregypt\/","article_published_time":"2022-12-25T19:03:33+00:00","og_image":[{"width":362,"height":463,"url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg","type":"image\/jpeg"}],"author":"Marwa Zein","twitter_card":"summary_large_image","twitter_creator":"@egyptcsrforum","twitter_site":"@egyptcsrforum","twitter_misc":{"Written by":"Marwa Zein","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/"},"author":{"name":"Marwa Zein","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec"},"headline":"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment","datePublished":"2022-12-25T19:03:33+00:00","dateModified":"2022-12-25T19:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"image":{"@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg","articleSection":["health","news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/","url":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/","name":"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment - Csr Egypt","isPartOf":{"@id":"https:\/\/csregypt.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg","datePublished":"2022-12-25T19:03:33+00:00","dateModified":"2022-12-25T19:03:33+00:00","description":"(EIB) has provided a \u20ac20 million venture debt loan facility to the Swedish company Affibody to develop biopharmaceuticals to treat cancer inflammatory diseases.","breadcrumb":{"@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#primaryimage","url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg","contentUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg","width":362,"height":463,"caption":"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/csregypt.com\/en\/eib-extends-e20-m-to-swedish-firm-to-develop-biopharmaceuticals-for-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/csregypt.com\/"},{"@type":"ListItem","position":2,"name":"EIB extends \u20ac20 m to Swedish firm to develop biopharmaceuticals for cancer treatment"}]},{"@type":"WebSite","@id":"https:\/\/csregypt.com\/#website","url":"https:\/\/csregypt.com\/","name":"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631","description":"The first portal for CSR in Egypt and Middle East","publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/csregypt.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/csregypt.com\/#organization","name":"CSR","url":"https:\/\/csregypt.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","contentUrl":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","width":1080,"height":1080,"caption":"CSR"},"image":{"@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/csregypt\/","https:\/\/x.com\/egyptcsrforum","https:\/\/www.instagram.com\/csr.egypt\/","https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/","https:\/\/www.pinterest.com.au\/csregypt\/","https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g"]},{"@type":"Person","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec","name":"Marwa Zein","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","caption":"Marwa Zein"},"sameAs":["http:\/\/marwazein1982@gmail.com"],"url":"https:\/\/csregypt.com\/en\/author\/marwa-zein\/"}]}},"jetpack_featured_media_url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/12\/8ffb8fa6-ed9b-46a2-a1a3-06e2995ce037.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/83806"}],"collection":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/users\/410"}],"replies":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/comments?post=83806"}],"version-history":[{"count":1,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/83806\/revisions"}],"predecessor-version":[{"id":83809,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/83806\/revisions\/83809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media\/83807"}],"wp:attachment":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media?parent=83806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/categories?post=83806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/tags?post=83806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}